Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09FAZ
|
||||
Former ID |
DAP000640
|
||||
Drug Name |
Azacitidine
|
||||
Synonyms |
Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Anticancer Agents
|
||||
Structure |
Download2D MOL |
||||
Formula |
C8H12N4O5
|
||||
InChI |
InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
|
||||
InChIKey |
NMUSYJAQQFHJEW-KVTDHHQDSA-N
|
||||
CAS Number |
CAS 320-67-2
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
13439, 596456, 3139592, 8140000, 8148227, 8149830, 8156757, 11335300, 11360539, 11364156, 11364964, 11366718, 11367526, 11369280, 11370088, 11372756, 11373127, 11374582, 11375688, 11377442, 11378259, 11461511, 11484628, 11488602, 11491324, 11492737, 11495076, 12013374, 14749656, 15019893, 17390033, 17397176, 17404599, 24278211, 24890525, 26612306, 26679741, 26752817, 29228037, 46509032, 47216641, 47662119, 47810606, 47885263, 48034961, 48259073, 48334340, 48413245, 48415593, 48422584
|
||||
ChEBI ID |
ChEBI:2038
|
||||
SuperDrug ATC ID |
L01BC07
|
||||
Target and Pathway | |||||
Target(s) | DNA (cytosine-5)-methyltransferase | Target Info | Inhibitor | [537058] | |
References | |||||
Ref 537058 | The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28. Epub 2009 Feb 5. | ||||
Ref 541877 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.